Asset Details
Do you wish to reserve the book?
Commonly used medications and endometrial cancer survival: a population-based cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Commonly used medications and endometrial cancer survival: a population-based cohort study
Do you wish to request the book?
Commonly used medications and endometrial cancer survival: a population-based cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Commonly used medications and endometrial cancer survival: a population-based cohort study
2017
Overview
Background:
Increasing incidence and new indications for existing drugs make it important to identify new adjuvant therapies for endometrial cancer (EC).
Methods:
This is a prospective cohort study of 3058 newly diagnosed EC cases from 1998 to 2010, identified through record linkages between the UK Clinical Practice Research Datalink, the National Cancer Research Datalink and death registrations from the Office of National Statistics. Using Cox regression models, unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for EC-specific survival.
Results:
Over a mean 6.1 (range 1–16) years of follow-up, there were 394 EC-specific deaths. There was no evidence of a significant association between post-diagnostic use of statins (adjusted HR 0.83, 95% CI 0.64, 1.08),
β
-blockers (adjusted HR 0.86, 95% CI 0.65, 1.13) or low-dose aspirin (adjusted HR 0.91, 95% CI 0.69, 1.20) and EC survival before or after adjustment for confounders. There were also no evidence of a dose–response association between these drug groups and EC survival.
Conclusions:
In this large UK population-based study, no significant associations were observed for post-diagnostic use of statins,
β
-blockers or low-dose aspirin and EC survival.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adrenergic beta-Antagonists - therapeutic use
/ Aged
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Aspirin
/ Aspirin - administration & dosage
/ Biomedical and Life Sciences
/ Death
/ Endometrial Neoplasms - diagnosis
/ Endometrial Neoplasms - mortality
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Oncology
/ Statins
/ Survival
